High levels of HDL-cholesterol (HDL-C) protect against coronary heart disease susceptibility, but the metabolic mechanisms underlying elevated HDL-C levels are poorly understood. We now report the turnover of isologous radioiodinated HDL apolipoproteins, apo A-I and apo A-II, in 15 female subjects on a metabolic diet with HDL-C levels ranging from 51 to 122 mg/dl. The metabolic parameters, fractional catabolic rate (FCR) and absolute synthetic rate (SR), were determined for apo A-I and apo A-II in all subjects.
Introduction
High HDL-cholesterol (HDL-C)' levels are a "protective" risk factor for coronary heart disease (1) . Women have higher HDL-C levels than men on average (2) , and this is believed to account for some of their advantage regarding atherosclerosis risk. Unfortunately, little is known about the metabolic basis underlying the high HDL-C state in women. HDL apolipoprotein turnover studies are the established method for studying in vivo metabolism ofHDL, but there have been published only four such studies of women with high HDL-C and they report on only a total of five women with HDL-C levels above the 80th percentile for age and sex (3) (4) (5) (6) . Because of the small number of subjects, usually being compared with only a few controls, it has been difficult to draw conclusions about the metabolic basis of high HDL-C.
In the current report, we have studied in vivo HDL apolipoprotein turnover in 15 individuals with HDL-C levels ranging from normal to very elevated (eight subjects above the 80th percentile). Since sex hormone therapy and gender are known to affect HDL-C levels and HDL apolipoprotein turnover parameters, we included only women and have excluded those taking exogenous estrogen. The subjects were studied on a metabolic diet, with a fixed content of fat and carbohydrate and without alcohol ingestion, to minimize variability from dietary influences. We found that HDL-C levels correlated inversely with the fractional catabolic rate (FCR) of both apo A-I and apo A-II but not with the absolute synthetic rates (SR) of either of these apoproteins.
Methods
Subjects. 15 female subjects were recruited from three sources: (a) patients from the clinic ofthe Laboratory ofBiochemical Genetics and Metabolism; (b) healthy, adult volunteers working on the staff at Rockefeller University or at neighboring institutions; (c) undergraduate students on a work-study program. All subjects were free from renal, thyroid, and immunologic disorders by history and laboratory screening. All but one of the subjects were also free from hepatic disease. This subject (No. 1) had a history of hepatic porphyria, which had been clinically silent on daily treatment with luteinizing hormone-releasing hormone antagonist for over 1 yr before the study. On this regimen, she had amenorrhea with estradiol levels in the borderline low to low-normal range. During the study she continued the treatment. However, it was later discontinued without a significant change in her HDL-C level. This suggested that the drug had no significant effect on her apo-HDL turnover. Subject 2 had partial hypopituitarism from successful removal of a craniopharyngioma several years earlier and was taking only physiologic replacement doses of hydrocortisone and vasopressin at the time ofthe study. She also had amenorrhea and mild symptoms of estrogen deficiency and was taking no estrogen supplements. None of the other subjects were taking medications known to alter lipid levels. The clinical aspects of these studies 18-24 h at 50,000 rpm in a 60 Ti rotor (Beckman Instruments, Inc., Fullerton, CA) at 4VC using solid KBr for sample density adjustment. The HDL was dialyzed against 0.15 M NaCi, 1 mM Na2EDTA, pH 7.4, and then delipidated by the following method. 1 ml of HDL preparation (4-20 mg protein/ml) was added dropwise to 5 ml of acetone/ethanol 1:1 at -150C in a polypropylene tube while vortexing. Another 8 ml of the acetone/ethanol was added and the tube inverted to mix the contents thoroughly. After standing at -15'C for 1 h the mixture was spun at 2500 rpm at 4VC for 5 min and the supernatant discarded. The precipitate was vortexed with 5 ml of acetone/ethanol (1: 1, -150C), and 8 ml ofacetone/ethanol was added. After standing as before for 1 h the mixture was centrifuged for 20 min and the supernatant was again discarded. If needed to remove any traces ofyellow in the precipitate this procedure was repeated a third time. Finally, the precipitate was vortexed with 5 ml of diethyl ether. The mixture was centrifuged as before, the supernatant aspirated, and the precipitate dried under N2 and stored at 4VC until used. To purify the HDL apolipoproteins, the precipitate was dissolved in 0.05 M Tris HCI, pH 8.2, in freshly deionized 6 M urea. This solution was passed through a 0.45-Am filter and applied to an anion exchange column, Mono Q (fast protein liquid chromatography, Pharmacia, Inc., Piscataway, NJ). Peaks corresponding to apo A-I and apo A-I1 were eluted using a Tris-HCl gradient, 0.05-0.SM, pH 8.2, in 6 M urea. Apo A-I and apo A-II were further purified by gel filtration chromatography on a Superose 12 column (fast protein liquid chromatography, Pharmacia, Inc.), in 0.05 M Tris HCl, pH 8.2, in 6 M urea. Purity was judged by overloaded silver-stained SDS-PAGE with a 10-15% acrylamide gradient (SDS-PAGE, Phast system, Pharmacia, Inc.). The purified apo A-I or apo A-II solution was either used promptly for iodination or was dialyzed against 1 mM ammonium bicarbonate, lyophilized and stored at -15°C until used.
Radioiodination was performed by the Bilheimer modification (7) of the McFarlane method (8) , with the apolipoprotein dissolved in the same buffer as used for column chromatography. After iodination, the protein solution was dialyzed against 0.15 M NaCl, 1 mM Na2EDTA, pH 7.4. Human serum albumin was added to a final concentration of 8 mg/ml, and the solution was put through a 0.22-jsm filter. The filtrate was tested for pyrogens by injection into rabbits or by the Limulus test (Pyrotell Limulus amebocyte lysate, Associates of Cape Cod Woods Hole, MA) (9), and sterility was tested by culture. The radiolabeled apo A-I and apo A-II contained on average 0.5 mol of iodine per mol of apolipoprotein. A previous study suggests that twice this degree of iodination has little effect on physical properties of apo A-I (10) . Over 99% of the radioactivity was precipitable by 17% trichloroacetic acid, and > 95% of the counts were within the specific apolipoprotein band on SDS/PAGE. Kinetic studies. The subjects were admitted to The Rockefeller University Hospital inpatient ward and kept on a natural food metabolic diet for 4 21 . The density distribution ofradiolabel was calculated as a percentage oftotal counts, and the results for the 10-min, 7-, and 14-d samples were averaged. These density fractions contained 1.7%, 89.0%, and 9.5% of the apo A-I and 1.4%, 91.6%, and 7.3% ofthe apo A-II label, respectively. The results did not differ significantly by time of sampling during the 14-d period.
Lipid, lipoprotein, and apolipoprotein determinations. On days 1, 3, 7, 10, and 14 of the turnover period, plasma was obtained after a 12-h overnight fast for measurement of lipid, lipoprotein, and apolipoprotein levels. Lipid and lipoprotein measurements were done on fresh, unfrozen specimens, while aliquots of plasma were immediately frozen at -70'C for apolipoprotein determinations at a later date. Total cholesterol and triglycerides were determined enzymatically using Boehringer Mannheim (Indianapolis, IN) kits. HDL-C was determined after apo B-containing lipoproteins were precipitated by the dextran sulfate method (17) . LDL plus HDL-C was determined on the infranatant after removing VLDL-C by airfuge ultracentrifugation (Beckman Instruments, Inc.). LDL-C was determined by subtracting the HDL-C from the cholesterol in the infranatant. VLDL-C was determined by subtracting the cholesterol in the infranatant from the total cholesterol. Cholesterol and HDL-C determinations were standardized by the Lipid Standardization Program of the Centers for Disease Control, Atlanta, Georgia (18).
Frozen aliquots of plasma were assayed for apo A-I and apo A-Il levels. Apo A-I levels were assayed by sandwich ELISA. A polyclonal goat antibody to human apo A-I (generously supplied by Dr. Peter Herbert, Brown University, Providence, RI) was purified by ammonium sulfate precipitation (19) and apo A-I affinity chromatography (CNBr sepharose, Pharmacia, Inc., using method ofthe manufacturer) and diluted 1:2,000 in coating buffer consisting of 15 mM Na2CO3, 35 mM NaHCO3, and 3 mM NaN3, pH 9.6 (made fresh weekly), to a final concentration of2.5 ,g antibody protein/ml. Microtiter plates (NUNC Immuno Plate I) were incubated overnight at 4°C with the antibody. The plates were then washed three times in Tween 20/phosphate-buffered saline solution, 1:2,000 vol/vol, pH 7.4 (Tween-PBS) using a Titertek Microplate Washer 120 (Flow Laboratories, Inc., McLean, VA). After washing, nonspecific binding sites were blocked by incubating the wells with bovine serum albumin (BSA) fraction V (Sigma Chemical Co., St. Louis, MO) 1 g/dl in PBS for 1 h at 37°C. The plates were washed as above and then plasma samples were added after serial dilution in Tween-PBS containing BSA 1 g/dl. Dilutions were made with a Cetus Pro/Pette autodilutor (Perkin-Elmer Corp., Norwalk, CT) in the range of 1:500 to 1:2,000 to bring at least two assay points within the linear range. After a 2-h incubation at 37°C, the plates were washed, and incubated for 2 h at 37°C with the polyclonal goat antibody to human apo A-I (3 gg protein/ml Tween-PBS BSA solution) conjugated with alkaline phosphatase by the one-step glutaraldehyde method (20) . The plates were then washed and incubated with phos-phatase substrate 104 (Sigma Chemical Co.), freshly dissolved at a concentration of 1 mg/ml in 0.5 mM MgC12-6H20, 3 mM NaN3, pH 9.8. After 30-60 min in subdued light at room temperature, color development was read at 410 nm in a Microplate Reader MR600 (Dynatech Precision Sampling Corp., Baton Rouge, LA). Assays were standardized with a reference serum pool from the Centers for Disease Control and two frozen control sera, whose apo A-I levels had been determined by three independent laboratories (Brown University, U. S. Department of Agriculture Human Nutrition Center on Aging, and Northwest LRC). The entire assay was rejected if the control samples were more than 15% from the target values. The coefficient of variation between assays was < 15% and, within assays, < 8%. Apo A-II levels were determined in the Northwest LRC laboratories by a radioimmunoassay based on a radial immunodiffusion assay (21) . Over the 2-wk turnover period, no temporal trends were observed in the lipid, lipoprotein, and apolipoprotein levels and the mean ofall five determinations was used in the data analysis.
Postheparin lipase activities. After 11 d on the 42% fat diet and 3 d before isotope injection, a postheparin lipase test was performed. Heparin sodium for injection, 1,000 U/ml (from porcine intestinal mucosa, Organon, Diagnostics, Inc., West Orange, NJ), was administered by intravenous bolus in a dose of 60 U/kg body weight. 15 min later, blood was drawn into tubes with Na2EDTA, immediately placed on ice, and spun at 2000 rpm for 20 min at 4VC to obtain "postheparin plasma." This was then immediately aliquotted and stored at -70°C until assay. The lipase assay is a modification of the method of Krauss (22) . This method utilizes a sonified substrate of glycerol tri phase and is given as micromoles free fatty acid liberated per milliliter plasma per hour. LPL activity is the difference between total activity and that remaining after antibody inhibition, whereas the latter is the hepatic lipase (HL) activity. A control postheparin plasma sample was run with each assay, and all results within a given assay were corrected by dividing by the ratio of the control results in that assay to the mean control results over 22 assays. If the control results in a given assay varied above or below the mean control results by > 23%, all results from that assay were discarded, and the samples were retested. All lipase activity results presented are the mean of two to four separate assays. The coefficient of variation for the control results in the 22 standardizing assays was 12.7% for total lipase activity and 14.1% for HL activity. Similar coefficients of variation were obtained in a small number of subject samples which were also assayed repeatedly.
Statistical analysis. Linear regression analysis was performed using the least squares method, and statistical significance was defined as a P value < 0.05. Calculations were performed on The Rockefeller University Hospital CLINFO system.
Results
The age, body mass index, lipid, and lipoprotein levels were determined for each subject during the metabolic diet period (Table I ). The subjects were selected to provide a wide range of HDL-C levels from 50 mg/dl upward. Mean HDL-C values ranged from 51 to 122 mg/dl, and seven of the subjects (Nos. 1-6 and No. 8) were in the top quintile for age and sex (23) . LDL-C, for which the subjects were not selected, also varied widely, from 70 to 532 mg/dl, although only subjects 1,2, and 7 had levels > 200 mg/dl. After 2 wk of diet equilibration, purified, radiolabeled apo A-I and apo A-II were given to the subjects by intravenous bolus injection. Over the ensuing 2 wk a die-away curve of plasma radioactivity for each apolipoprotein for each subject was plotted. The apo A-I and apo A-II levels were measured and the metabolic parameters FCR and SR calculated as described in Methods. These results are presented in Table II . Wide ranges in each of these values also were seen. We evalu- ated parameters of HDL composition and ofendothelial lipase activity, since these are known to vary with HDL levels and may therefore relate to variability in HDL metabolism. An index of the ratio of core to surface components, and thereby of HDL particle size, may be obtained by dividing HDL-C, which predominantly reflects core cholesteryl ester, by the sum of apo A-I and apo A-II levels, which together account for 90% of the surface apoprotein. Since HDL particles are heterogeneous in the relative amounts of apo A-I and apo A-II, the ratio of plasma apo A-I to apo A-II level ratio provides a measure of this heterogeneity. Table III shows these indices of HDL composition and the postheparin plasma lipase activities during the metabolic diet. Among the lipoprotein and apoprotein levels, a highly significant correlation was found between HDL-C and the apo A-I level (r = 0.93, P < 0.001) and a positive trend of borderline significance between HDL-C and the apo A-II level (r = 0.47, P = 0.07). The relation between apo A-I and apo A-II levels was not significant (r = 0.37, P = 0.17).
Correlation analyses were performed to see which metabolic parameters best predicted levels of HDL-C, apo A-I, and apo A-Il. HDL-C levels correlated inversely and highly significantly with apo A-I FCR (r = -0.75, P < 0.001) and also significantly with apo A-II FCR (r = -0.54, P = 0.036) (Fig. 1) . HDL-C levels did not correlate significantly with the SR of either apo A-I or apo A-II (r = 0.09 and r = -0.16, respectively). Apo A-I levels correlated inversely and significantly with apo A-I FCR (r = -0.64, P = 0.01), but not significantly with apo A-I SR (r = 0.30, P = 0.28) (Fig. 2) . In contrast, apo A-II levels were not significantly correlated with apo A-II FCR (r = -0.38, P = 0.16) whereas they correlated strongly and directly with apo A-II SR (r = 0.65, P = 0.009).
The interrelationships among the metabolic parameters of HDL were explored. Despite the wide range ofthe FCR values, Correlations between apo A-I and apo A-II FCR and SR and two parameters of HDL composition, the HDL-C/apo A-I + apo A-II ratio and the apo A-I/apo A-II ratio, were next examined. The only significant correlations found were those between the FCRs of apo A-I and apo A-II and the HDL-C/ apo A-I + apo A-II ratio (r = -0.69, P = 0.005 and r = -0.61, P = 0.015, respectively) (Fig. 3) .
Correlations of parameters of HDL metabolism and composition with postheparin LPL and HL activities were next examined. LPL did not correlate significantly with the FCR of apo A-I or ofA-II (r = -0.27, P = NS and r = -0.40, P = 0. 13, respectively) or with their SR (r = -0.04, P = NS and r = -0.45, P = 0.09, respectively). HL also failed to correlate significantly with apo A-I or apo A-Il FCR (r = 0.41 and 0. 14) or SR (r = -0.10 and -0.22) in these subjects. Despite the lack of correlation with the metabolic parameters, LPL activity did correlate with the HDL-C/A-I + A-Il ratio (r = 0.61, P = 0.015) and with the apo A-I/apo A-Il ratio (r = 0.68, P = 0.005). HL failed to correlate with the HDL-C/A-I + A-II ratio (r = -0.04) or the A-I/A-II ratio (r = -0.19).
One of the subjects (No. 1) was taking a medication to alter her sex hormone levels. Her regimen simply rendered her hormonal status like the postmenopausal subjects (Nos. 4, 7, 15), and we have not excluded her from the principle analyses. Nevertheless, to ensure she did not bias the results, we repeated the correlation analyses excluding her. The correlations of HDL-C with the FCR of apo A-I and apo A-II were essentially unchanged (r = -0.72 and -0.60, P = 0.004 and 0.02, respectively), as were those of HDL-C with the SR of apo A-I and apo A-II (r = -0.14 and 0.32, respectively). Similar small changes were seen in the correlation between apo A-I and apo A-II levels and the corresponding SR (r = 0.18 and 0.65, respectively) and FCR (r = -0.53 and -0.40, respectively). The correlations of the FCR of apo A-I and of apo A-II with the HDL-C/A-I + A-Il ratio also differed little (r = -0.59 and -0.63, respectively). The correlation between LPL and the HDL-C/A-I + A-II and A-I/A-II ratios, however, became nonsignificant (r = 0.31 for both relationships).
Discussion
The principal goal of this study was to clarify the mechanism responsible for high HDL-C levels. To avoid confounding variables known to affect HDL-C levels, our analysis is based upon data obtained in women consuming a metabolic diet, who were not consuming alcohol or taking exogenous estrogen. The simple metabolic model used to analyze our tracer data provides a good measure of overall metabolism of HDL while minimizing possible modeling artefacts. Although this method does not facilitate exploration of metabolic heterogeneity of HDL, it clearly delineates basic aspects of its metabolism. As with all turnover studies, interpretation of these data rests ratio of apo A-I to apo A-II levels, postheparin LPL, and endothelial HL activities for each study subject are indicated. upon the assumption that the metabolism ofthe labeled tracer is equivalent to that of its unlabeled counterpart. We found that HDL-C levels correlated inversely with the FCR of apo A-I and apo A-II but not with the SR of either apoprotein.
Plasma apo A-I levels also had a strong inverse correlation with apo A-I FCR but no significant correlation with apo A-I SR. In contrast, apo A-II levels did not correlate with apo A-II FCR but had a strong positive correlation with apo A-1I SR.
There are few studies in the literature characterizing HDL apolipoprotein turnover parameters in high HDL-C subjects.
Fidge and co-workers (3) reported on one female subject with upper quintile HDL-C levels for age and sex. This person had a normal SR but an FCR in the lower range of normal for both apo A-I and apo A-II. Unfortunately, the normal comparison group was small, comprising just three female subjects. Rao and colleagues studied two women with high HDL-C levels, and one appeared to have an elevated SR, whereas the other had depressed FCR of both apo A-I and apo A-II (4). The normal control group, however, consisted ofjust two subjects.
Schaefer and co-workers (5) studied one woman with border- (Fig. 1) . The correlation between HDL-C and apo A-I levels also suggests that the latter would also be primarily regulated by apo A-I FCR; indeed, this is what was found (Fig. 2) . Schaefer previously reported an inverse relationship between apo A-I levels and apo A-I FCR in subjects with normal HDL-C (5). The current study demonstrates that this relationship also holds for the upper range of HDL-C levels.
The second important implication of our data is that the predominant mechanisms of metabolic regulation of apo A-I and apo A-II levels greatly differ. Apo A-I levels correlate with apo A-I FCR but not with apo A-I SR, while apo A-II levels correlate with apo A-II SR but not with apo A-II FCR (Fig. 2) . While certain differences in these relationships might be expected, given the lack of significant correlation between apo A-I and apo A-Il levels, the strong divergence in apparent metabolic mechanisms is striking. This is especially so given that (a) both apolipoproteins are frequently found on the same HDL particle, (b) the FCR of apo A-I correlates strongly with the FCR ofapo A-II, and (c) there is a correlation ofborderline significance between the SR of apo A-I and the SR of apo A-Il. The differences between apo A-I and apo A-Il metabolism might relate to the substantial heterogeneity of HDL particles. The simple modeling approach of this study does not test directly for metabolic heterogeneity. Possibly for this reason, our analysis does not provide an explanation of these intriguing disparities. Yet, since plasma levels of both apo A-I (24, 25) and apo A-Il (26) are reported to correlate inversely with atherosclerosis risk, our data do suggest that both low apo A-I FCR and high apo A-II SR may play important roles in protection against atherosclerosis. Another, less striking, metabolic difference between apo A-I and apo A-II in this study is that the FCR of apo A-I is on average 25% faster than the FCR of apo A-II (P < 0.0001). This confirms previous reports of other groups who have found the apo A-I FCR higher by 10-39% (3, 5, 6) .
The current study may also provide some insight into the mechanism of regulation of HDL apolipoprotein FCR. A significant inverse relationship was found between the HDL-C/ A-I + A-Il ratio and the FCR of apo A-I and apo A-II ( Figure  3) . Thus, larger HDL, with a greater core to surface ratio, may be catabolized more slowly. If this relationship is causal, it implies that lipid-rich HDL is less susceptible to catabolism. Lipid enrichment of HDL may alter apolipoprotein conformation (27) , which could hide epitopes necessary for catabolism (28) , as seen in the VLDL-IDL-LDL cascade (29) (30) (31) . Alternatively, a primary decrease in HDL catabolism could result in extra lipid accumulation in HDL. This might happen by prolonged exposure to potential lipid sources, such as chylomicrons or peripheral tissues.
HDL-C levels have been correlated directly with levels of LPL (32, 33) and inversely with HL (33) (34) (35) . It has been shown that LPL favors the formation of large lipid-rich HDL, HDL2, from small lipid-poor HDL3 (36, 37) and the opposite for HL (38, 39 port also was studied on estrogen therapy, during which she had a 63% drop in HL, a 42% decrease in apo A-I FCR, and a 37% decline in apo A-I SR, with little change in LPL or the metabolism of apo A-Il (40) . In a contrasting study of five women, Schaefer and colleagues (41) reported a 44% decrease in HL with estrogen treatment but found only an increase in HDL apoprotein synthetic rate and no change in FCR. Saku and colleagues (42) found that a gemfibrozil-induced increase in LPL correlated with increased apo A-I and apo A-Il SR. The same laboratory in a related study reported a positive correlation ofapo A-I and apo A-II FCR with postheparin plasma HL in a cross-sectional study of hypertriglyceridemic and normal subjects (43) . The lack of significant correlation between HL activity and apo HDL FCR in our study suggests that variability in HL activity may be less important in controlling HDL metabolism in subjects with high HDL-C levels. It is of interest to consider the relationship of HDL apolipoprotein metabolic parameters to coronary heart disease (CHD) risk. It has been argued that since women have higher HDL-C levels and apo A-I SR but lower CHD risk than men that an increase in HDL apo A-I synthesis may protect against CHD. In our study in women, high HDL-C levels appear to be determined by reduced apo A-I FCR and we infer that variability in apo A-I FCR is more closely associated with CHD risk. Two previous observations may favor this inference. The administration ofexogenous estrogen, which increases HDL-C levels and apo A-I SR (41), may increase rather than decrease CHD risk, at least in men with established atherosclerosis (44).
In addition, saturated fat feeding in humans increases HDL-C levels by increasing apo A-I SR (Brinton, E. A., S. Eisenberg, and J. L. Breslow, unpublished data) and is known to increase rather than decrease CHD risk (45, 46) . Since individuals with elevated HDL-C levels are known to be at reduced risk of atherosclerosis, our data suggest that reduced fractional clearance of apo A-I and apo A-II, and thus possibly of the entire HDL particle, may be an important metabolic mechanism of this protection.
